Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Settles with Sonic Healthcare over Patent Lawsuit

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled with a group of companies associated with Sonic Healthcare over a patent infringement lawsuit.

As a result, the lawsuit, which was filed in January 2011 in US District Court for the Western District of Texas, has concluded. Terms of the settlement were not disclosed.

The lawsuit pertains to the Australian test maker's patent on non-coding DNA technology.

"The patent assertion program remains a strong and reliable source of non-dilutive funding for GTG," Paul MacLeman, CEO of GTG, said in a statement. "The outcome of the suit against the Sonic affiliates demonstrates our commitment to pursue a vigorous and geographically comprehensive assertion program."

The company added that it is "progressing well" on another lawsuit filed in May 2011 against 10 companies, also alleging infringement of its non-coding DNA patent.

GTG has settled with three parties in that case: Navigenics, Hologic, and Eurofins STA Laboratories. It said that it has licensed its technology to more than 60 companies worldwide and generated more than A$73 million (US$78 million) to date in licensing revenue.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.